ESOT

What can we help you find?

Leading the way in transplantation

Filter results for:

ELTR – A Register for all Liver Transplantations performed in Europe

The European Liver Transplant Registry (ELTR) is the official database of ELITA. The idea for an ELTR was brought up at the meeting of the European Society for Organ Transplantation (ESOT) in Munich, 1985. A group of liver transplant professionals, including representatives from the pioneering liver transplant centers in Europe, decided to create the ELTR with the following objectives :

– To register all liver transplantations performed in Europe
– To provide a link between European liver transplant centers
– To stimulate scientific research and publications based on the European experience.

Paul Brousse Hospital (Villejuif, France) was designated to manage and analyse the data of ELTR since its creation. Two years after it was founded, ELTR had collected information on all liver transplant recipients performed in 32 European centers, which led to a landmark paper in the Lancet (Lancet 1987; 2 : 674).

Currently, the ELTR is one of the oldest European wide medical registries. ELTR includes data from 170,000 liver transplants performed in 153,000 patients from 171 centres in 32 countries. The questionnaire contains data on indication for transplantation, donor characteristics, technical aspects of liver transplantation, cause of death or graft failure and initial and maintenance immunosuppression. The ELTR gives since more than 35 years, the critical information on the outcome and the evolution of liver transplantation in Europe. While the data have been initially obtained with a center-driven approach, since several years a large part of them (>75%) are shared with Organ Sharing Organizations (*) and the remainder are directly retrieved from the liver transplant centers through an electronic data capture system.

(*)
– United Kingdom Blood and Transplant Authority (NHSBT) www.nhsbt.nhs.uk
– Spanish “Organizaciòn Nacional de Transplantes” (ONT) www.ont.es
– French “Agence de la Biomédecine” (ABM) www.agence-biomedecine.fr
– Deutch “Nederlandse Transplantatie Stichting” (NTS) www.transplantatiestichting.nl
– Eurotransplant Foundation (Austria, Belgium, Croatia, Germany, Luxembourg, Netherlands,     and Slovenia) www.eurotransplant.org
– Scanditransplant (Denmark, Finland, Norway, and Sweden) www.scandiatransplant.org


ELTR Publications

76- ELITA-ELTR COVID-19 Registry. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study. Belli LS, Fondevila C, Cortesi PA, Conti S, Karam V, Adam R, Coilly A, Ericzon BG, Loinaz C, Cuervas-Mons V, Zambelli M, Llado L, Diaz F, Invernizzi F, Patrono D, Faitot F, Bhooori S, Pirenne J, Perricone G, Magini G, Castells L, Detry O, Cruchaga PM, Colmenero J, Berrevoet F, Rodriguez G, Ysebaert D, Radenne S, Metselaar H, Morelli C, De Carlis L, Polak WG, Duvoux C;. Gastroenterology. 2020 Dec 9:S0016-5085(20)35514-1. https://pubmed.ncbi.nlm.nih.gov/333…

75- Liver Transplantation for Acute Intermittent Porphyria. Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, Meersseman W, Melum E, Ołdakowska-Jedynak U, Reiter FP, Colmenero J, Sanchez R, Herden U, Langendonk J, Ventura P, Isoniemi H, Boillot O, Braun F, Perrodin S, Mowlem E, Wahlin S. Liver Transpl. 2020 Dec 1. https://pubmed.ncbi.nlm.nih.gov/332…

74- Characteristics, trends and Outcomes of Liver Transplantation for Primary sclerosing cholangitis in female vs male patients: An analysis from the European Liver Transplant Registry. Berenguer M, Di Maira T, Baumann U, Mirza DF, Heneghan MA, Klempnauer JL, Bennet W, Ericzon BG, Line PD, Lodge PA, Zieniewicz K, Watson CJE, Metselaar HJ, Adam R, Karam V, Aguilera V. Transplantation. 2020 Nov 13. https://pubmed.ncbi.nlm.nih.gov/331…

73- Reply to Rodriguez-Peralvarez et al. Polak WG, Fondevila C, Karam V, Adam R, Belli LS, Duvoux C; for European Liver, Intestine Transplant Association (ELITA), the COVID-19 ELITA Study Group. Transpl Int. 2020 Oct 9:10.1111/tri.13765. https://pubmed.ncbi.nlm.nih.gov/330…

72- Pommergaard HC, Rostved AA, Adam R, Salizzoni M, Bravo MAG, Cherqui D, De Simone P, Houssel-Debry P, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O’Grady J, Karam V, Duvoux C, Thygesen LC. Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry. Liver Cancer. 2020 Aug;9(4):455-467. https://pubmed.ncbi.nlm.nih.gov/329…

71- Temporal Trends and Outcomes in Liver Transplantation for Recipients with Human Immunodeficiency Virus Infection in Europe and United States. Campos-Varela I, Dodge JL, Berenguer M, Adam R, Samuel D, Di Benedetto F, Karam V, Belli LS, Duvoux C, Terrault NA. Transplantation. 2019 Dec 31. https://pubmed.ncbi.nlm.nih.gov/329…

70- What did the European Liver Transplant Registry (ELTR) Bring to Liver Transplantation? Lerut J, Karam V, Cailliez V, Bismuth H, Polak WG, Gunson B, Adam R. Transpl Int. 2020 Aug 7. https://pubmed.ncbi.nlm.nih.gov/327…

69- Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. Polak WG, Fondevila C, Karam V, Adam R, Baumann U, Germani G, Nadalin S, Taimr P, Toso C, Troisi RI, Zieniewicz K, Belli LS, Duvoux C. Transpl Int. 2020 Jul 1:10.1111/tri.13680. https://pubmed.ncbi.nlm.nih.gov/326…

68- COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Belli LS, Duvoux C, Karam V, Adam R, Cuervas-Mons V, Pasulo L, Loinaz C, Invernizzi F, Patrono D, Bhoori S, Ciccarelli O, Morelli MC, Castells L, Lopez-Lopez V, Conti S, Fondevila C, Polak W. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):724-725. https://pubmed.ncbi.nlm.nih.gov/325…

67-Influence of donor and recipient gender on liver transplantation outcomes in Europe. Germani G, Zeni N, Zanetto A, Adam R, Karam V, Belli LS, O’Grady J, Mirza D, Klempnauer J, Cherqui D, Pratschke J, Jamieson N, Salizzoni M, Hidalgo E, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FSJ, Villa E, Burra P. Liver Int. 2020 May 16. https://pubmed.ncbi.nlm.nih.gov/324…

66-Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. Heinemann M, Adam R, Berenguer M, Mirza D, Malek-Hosseini SA, O’Grady JG, Lodge P, Pratschke J, Boudjema K, Paul A, Zieniewicz K, Fronek J, Weiss KH, Karam V, Duvoux C, Lohse A, Schramm. Liver Transpl. 2020 Jul;26(7):866-877. https://pubmed.ncbi.nlm.nih.gov/321…

65- Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An Extension Study. Adam R, Karam V, Cailliez V et al. Transplantation 2019

64- Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand? Durand F, Pavesi M, Cheung R. Journal of Hepatology 2019

63- Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. Haldar D, Kern B, Hodson J et al. Journal of Hepatology 2019

62- Heterogeneity of Bile Duct Management in the Development of Ischemic Cholangiopathy After Liver Transplantation: Results of a European Liver and Intestine Transplant Association Survey. Meurisse N, Monbaliu D, Berlakovich G. et al. Transplant Proceedings 2019

61- Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Harms MH, Janssen QP, Adam R et al. Alimentary Pharmacology & Therapeutics 2019

60- 2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Adam R, Karam V, Cailliez V et al. Transplant International 2018

59- Predictive Factors for Survival in Children Receiving Liver Transplants for Wilson’s Disease: A Cohort Study Using European Liver Transplant Registry Data. Pfister ED, Karch A, Adam R et al. Liver Transplantation 2018

58- A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over! Terrault NA, Pageaux GP. Journal of Hepatology 2018

57- Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Belli LS, Perricone G, Adam R et al. Journal of Hepatology 2018

56- A Systematic Review and Meta-Analysis of Cold In Situ Perfusion and Preservation of the Hepatic Allograft: Working Toward a Unified Approach. Adam R, Cailliez V, Segev D, Karam V. Liver Transplantation 2018

55- Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Pommergaard HC, Rostved AA, Adam R et al. HPB (Oxford) 2018

54- Outcomes of left split graft transplantation in Europe: report from the European Liver Transplant Registry. Angelico R, Nardi A, Adam R et al. Transplant International 2018

53- Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Pommergaard HC, Rostved AA, Adam R et al. Transplant International 2018

52- Survival of children after liver transplantation for hepatocellular carcinoma. Baumann U, Adam R, Duvoux C et al. Liver Transplantation 2018

51- Evaluation of HTK Preservation Solutions in Liver Transplantation: A Long-Term Propensity-Based Analysis of Outcome From the European Liver Transplant Registry. Adam R, Cailliez V and Karam V. American Journal of Transplantation 2017

50- More is less: Calling for joining forces for rare pediatric liver tumors research. De Ville de Goyet J, Morland B, Czauderna P. Liver Transplantation 2017

49- Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry. Lai Q, Feys E, Karam V, Adam R et al. Transplantation 2017

48- Early and Late Factors Impacting Patient and Graft Outcome in Pediatric Liver Transplantation: Summary of an ESPGHAN Monothematic Conference. McLin VA, Allen U, Boyer O et al. Journal of Pediatric Gastroenterology and Nutrition 2017

47- Liver Transplantation for Hepatic Trauma: A Study From the European Liver Transplant Registry. Krawczyk M, Grąt M, Adam R et al. Transplantation 2016

46- Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. Mantel HT, Westerkamp AC, Adam R et al. PLoS One 2016

45- Comparison of Two Questionnaires on Informed Consent in “Marginal” Donor Liver. Bruzzone P, Balla A, Quaresima S et al. Transplant Proceedings 2016

44- Liver transplantation for adenomatosis: European experience. Chiche L, David A, Adam R et al. Liver Transplantation 2016

43- Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Adam R, Karam V, Delvart V et al. American Journal of Transplantation 2015

42- Reply to Letter Regarding “Compared Efficacy of Preservation Solutions in Liver Transplantation: A Long-Term Graft Outcome Study From the European Liver Transplant Registry”. Adam R, Delvart V, Karam V. American Journal of Transplantation 2015

41- Regarding ‘‘Compared efficacy of preservation solutions in liver transplantation: A long-term graft outcome study from the European Liver Transplant Registry.’’ Nashan B, Spetzler V, Schemmer P et al. American Journal of Transplantation 2015

40- Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. Adam R, Delvart V, Karam V et al. American Journal of Transplantation 2015

39- Is liver transplantation justified in septuagenarians? Karam V, Delvart V and Adam R. Le Courrier de la Transplantation 2013

38- A preliminary European Liver and Intestine Transplant Association-European Liver Transplant Registry study on informed recipient consent and extended criteria liver donation. Bruzzone P, Giannarelli D, Adam R et al. Transplant Proceedings 2013

37- The difficulty in defining extended donor criteria for liver grafts: the Eurotransplant experience. Silberhumer GR, Rahmel A, Karam V et al. Transplant International 2013

36- Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Le Treut YP, Grégoire E, Klempnauer J et al. Annals of Surgery 2013

35- Incorporation of donor risk into liver allocation algorithms. Braat AE, Blok JJ, Rahmel AO et al. American Journal of Transplantation 2013

34- Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation–the European Liver Transplant Registry experience. Orlando G, Adam R, Mirza D et al. Transplantation 2013

33- Focus. Daniel Shouval. Journal of Hepatology 2013

32- Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. Burra P, Germani G, Adam R et al. Journal of Hepatology 2013

31- Liver transplantation for unresectable hepatocellular carcinoma in normal livers. Mergental H, Adam R, Ericzon BG et al. Journal of Hepatology 2012

30- The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Dutkowski P1, Schlegel A, Slankamenac K et al. Annals of Surgery 2012

29- The Eurotransplant donor risk index in liver transplantation: ET-DRI. Braat AE, Blok JJ, Putter H et al. American Journal of Transplantation 2012

28- Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). Adam R, Karam V, Delvart V et al. Journal of Hepatology 2012

27- Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. Germani G, Theocharidou E, Adam R et al. Journal of Hepatology 2012

26- Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region. Blok JJ, Braat AE, Adam R et al. Liver Transplantation 2012

25- Liver transplantation for erythropoietic protoporphyria in Europe. Wahlin S, Stal P, Adam R et al. Liver Transplantation 2011

24- European Liver and Intestine Transplant Association. Excellent survival after liver transplantation for isolated polycystic liver disease: A European Liver Transplant Registry study. Van Keimpema L1, Nevens F, Adam R et al. Transplant International 2011

23- Liver transplantation and vascular tumours. Bonaccorsi-Riani E, Lerut JP. Transplant International 2010

22- Liver transplantation for colorectal liver metastases: revisiting the concept. Foss A, Adam R, Dueland S. Transplant International 2010

21- Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Mergental H, Porte RJ. Transplant International 2010

20- European Liver Intestine Transplant Association. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Schramm C, Bubenheim M, Adam R et al. Liver Transplantation 2010

19- Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Burra P, Senzolo M, Adam R et al. American Journal of Transplantation 2010

18- Liver transplantation: the current situation. Adam R, Hoti E. Seminars in Liver Disease 2009

17- Liver transplantation for primary and metastatic liver cancers. Hoti E, Adam R. Transplant International 2008

16- European Liver Transplant Registry. The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Lerut JP, Orlando G, Adam R et al. Annals of Surgery 2007

15- Towards a better liver transplant allocation system. Burroughs AK, Marelli L, Cholongitas E. Liver Transplantation 2007

14- Living liver donor mortality: where do we stand? Bramstedt KA. American Journal of Gastroenterology 200615- Documented deaths of hepatic lobe donors for living donor liver transplantation. Trotter JF, Adam R, Lo CM, Kenison J. Liver Transplantation 2006

13- Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Melzi ML1, Kelly DA, Colombo C et al. Transplant International 2006

12- The place of liver transplantation in Caroli’s disease and syndrome. De Kerckhove L, De Meyer M, Verbaandert C  et al. Transplant International 2006

11- European Liver Transplant Association. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Burroughs AK, Sabin CA, Rolles K et al. Lancet 2006

10- Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Mutimer DJ, Gunson B, Chen J et al. Transplantation 2006

9- European Liver Transplant Association. Liver Transplantation for Hereditary Hemorrhagic Telangiectasia: Report of the European Liver Transplant Registry. Lerut J, Orlando G, Adam R et al. Annals of Surgery 2006

8- Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. Mentha G, Giostra E, Majno PE et al. Journal of Hepatology 2006

7- Liver transplantation in Europe: is there a room for improvement? Adam R, Lucidi V, Karam V. Journal of Hepatology 2005

6- European Liver Transplant Association. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Adam R, McMaster P, O’Grady JG et al. Liver Transplantation 2003

5- Assessing the quality of data in a transplant registry: The European Liver Transplant Registry. Van der Meulen JH1, Jacob M, Copley L. Transplantation 2003

4-  European Liver Transplant Association. Quality control of the European Liver Transplant Registry: results of audit visits to the contributing centers. Karam V, Gunson B, Roggen F et al. Transplantation 2003

3- Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Adam R, Cailliez V, Majno P et al. Lancet 2000. Erratum in: Lancet 2001

2- Liver Transplant Registry Report. Gordon RD, Bismuth H. Transplant Proceedings 1991

1- Hepatic transplantation in Europe: first report of the European Liver Transplant Registry. Bismuth H et al. Lancet 1987

More information on the ELTR can be obtained at www.eltr.org

Regulations for the ELITA /ELTR studies.

How to apply for endorsement of a research project by ELITA

  1. A request should be addressed to the Secretary of ELITA, together with the study protocol.
  2. The study should have a multinational and multicentre character.
  3. The study should focus on the patients undergoing liver or intestine transplantation.
  4. The principal investigator must be member of ELITA.
  5. The study protocol should be approved by all ELITA Scientific Committee. Once the request has been approved by the ELITA Scientific Committee, the project will be endorsed under the following conditions:
    • In the official correspondence it is stated that “This study is endorsed by the European Liver and Intestine Transplant Association (ELITA)”. This should be accompanied by the official logo of ELITA.
    • The ELITA Board is regularly updated about the results of the study (see below). In scientific publications arising from the study, it will be acknowledged that the study was endorsed by the European Liver and Intestine Transplant Association (ELITA).
    • The initiator (the principal investigator) of the study remains fully responsible and accountable for the study. ELITA bears no direct or indirect responsibility for the study.

Regulations for ELTR-based Studies and Publications:

Who can access to the data:

  1. ELTR data are available to ELITA members to perform scientific studies, which should preferably lead to a publication in a peer-reviewed journal.
  2. Third parties (not ELITA members) will be asked to pay a fee for the collection of requested data depending on the extent of dataset and/or for statistical evaluation of the work.

 Dataset rules:

  1. The dataset is confidential, and it might be only used for the purpose of approved study by the ELITA Board.
  2. No additional studies are allowed to be performed with the dataset.
  3. In case the requested data is not (completely) available in the ELTR database, it is allowed to approach ELTR centres for additional data. A request to the centres should be presented on ELITA/ELTR letterhead and should be co-signed by one of the ELITA Board members and by the ELTR General Manager.

How to obtain the data:

To obtain data, a written request should be addressed to the ELITA Secretary with copy to the ELTR General Manager.
The request should contain:

  1. Title and full description of the study.
  2. Supporting letter by the program director.
  3. Names and affiliations of the investigators (depending on the type of the study, max. 2- 3). At least one of the authors should be a recognized specialist in the subject.
  4. A disclosure statement regarding potential conflicts of interest (such as financial affiliations with pharmaceutical companies)

Once the request is submitted:

  1. The ELITA Secretary sends the request to the ELITA Scientific Committee who reviews the request and give its feedback.
  2. Once the scientific evaluation is achieved, the ELITA Scientific Committee assigns one Board member who is the liaison person for the conductance of the study and represents ELITA as a co-author of the study.
  3. An official notification of the decision of the ELITA Board is sent to the investigator from ELITA Secretary. If the study has been accepted, the investigators are requested to sign an agreement with the ELITA regarding the study conduction and publication policy.

 Data Fees:

  1. A fee of 500 or 1000 € per dataset for paying and non-paying ELTR members/centres, respectively, or 2000 € for centres not contributing to the ELTR database will be transferred to the ELITA account. If additional statistical analysis is requested from ELTR, this will be charged at an hourly rate.
  2. For the request from third parties (i.e. industry) a different fee applies to be determined according to the type of applicant (ELTR sponsor or not) and the size of the project.
  3. No data fees will be charged for study requests from ESPAGHAN members.

Authorship guidelines of any publication based on ELTR data (abstracts of full papers):

Authorship guidelines of any publication based on ELTR data is regulated as follows

  1. First, second and last authorship for researchers performing the study. Those ones are who design the study, collect and analyse data and write the paper.
    The third and the fourth position will be reserved for ELTR member and ELITA liaison person (persons who proofreads the paper, controls adequate conductance, takes care of communication) and it will be defined by the ELITA Board according to the extent of involvement by the ELTR and their expertise in the field of the request.
  2. As many authors as possible included as allowed by the journal. In the case that the journal has a limitation with the number of authors, the authorship will be stablished according to the number of patients included in the study and only one author per centre. After the last author, the statement “for the European Liver and Intestine Transplant Association (ELITA)” should be added.
    Nevertheless, all centres and authors that have participated in the study should be listed in a paragraph after discussion/conclusion and before references mentioning at first the program director and one or two of the collaborators.
  3. The title of the paper should mention the topic of the study with the mention: “an ELTR study
  4. The text below should be added in the manuscript: “This study is endorsed by the European Liver and Intestine Transplant Association (ELITA). We thank all investigators and their participating center. The European Multicenter Study Group consisted of the following centers and committees: [The structure of the citation will be referred as follow: country, institutions per country and authors per institution]. All collaborators should be mentioned in major research websites (i.e. PUBMED, Scopus), if its editorial policy accept”.
  5. The paragraph entitled “Aknowledgements” containing the text below must be added at the end of each ELTR based on manuscript: “The ELTR is supported by a grant from…: (partners to be reviewed by ELITA Governing Board every year). The Organ Sharing Organizations: the French ABM (Sami Djabbour and Alain Jolly), the Dutch NTS (Cynthia Konijn), the Eurotransplant Foundation (Marieke Van Meel and Erwin de Vries), the Spanish ONT (Gloria de la Rosa), the UK- Ireland NHSBT (Mike Chilton and Julia Micciche) are acknowledged for the data cross-check and sharing with the ELTR.”
  6. These rules also apply when only a part of the published data is available in the ELTR database.

Study performance:

  1. ELITA suggests the following timeline for conducting an ELTR-based study:
    • After the payment of the fee the request dataset will be sent to the investigator.
    • Data collection from ELTR: 3 months since the dataset has been sent to the participants.
    • Additional data collection from the centres (if necessary): 6 months
    • Data evaluation and analysis: 6 months
    • Preparation of the manuscript: 5 months
  1. ELITA requires an update on study activities every 6 months beginning from the date of approval of the study, which has to be sent to the ELITA Secretary, to the assigned Board member and to the ELTR Data Manager.
  2. If no progress has been made with the study for 2 years, the ELITA Board has the right to cancel the study.

Publication methodology:

  1. Manuscripts should always be presented to the ELITA Board for approval prior to submission.
  2. The choice for a journal is made in agreement with the ELITA Board
  3. If the manuscript has been sent out for publication or published without the acceptance of ELITA/ELTR, ELITA has a right to contact a journal where the manuscript has been sent and to remove this publication.
  4. Similar rules apply when abstracts are presented to congresses.

Download the above regulations here.

Download the ELTR/ELITA study agreement here.